Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

被引：0
|
作者：
Shayma Kazmi
Debanjana Chatterjee
Dheeraj Raju
Rob Hauser
Peter A. Kaufman
机构：
[1] Cancer Treatment Centers of America,US Health Economics Outcomes Research and Real World Evidence
[2] Eisai Inc.,Larner College of Medicine, Division of Hematology/Oncology
[3] Cancer Treatment Centers of America Global,undefined
[4] Inc.,undefined
[5] University of Vermont Cancer Center,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 184卷
关键词：
Metastatic breast cancer; Visceral metastases; Overall survival; Eribulin; Real-world evidence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：559 / 565
页数：6
相关论文
共 50 条
  • [1] Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
    Kazmi, Shayma
    Chatterjee, Debanjana
    Raju, Dheeraj
    Hauser, Rob
    Kaufman, Peter A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 559 - 565
  • [2] Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
    Shayma Kazmi
    Debanjana Chatterjee
    Dheeraj Raju
    Rob Hauser
    Peter A. Kaufman
    [J]. Breast Cancer Research and Treatment, 2021, 187 : 603 - 603
  • [3] Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine (vol 184, pg 559, 2020)
    Kazmi, Shayma
    Chatterjee, Debanjana
    Raju, Dheeraj
    Hauser, Rob
    Kaufman, Peter A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (02) : 603 - 603
  • [4] Real-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine
    Kazmi, S. M.
    Chatterjee, D.
    Alexis, K.
    Raju, D.
    Wang, E.
    Knoth, R. L.
    Hauser, R. S.
    Kaufman, P. A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 133 - 133
  • [5] The effect of age on overall survival (OS) in patients with metastatic breast cancer (MBC) treated with capecitabine
    Blum, J. L.
    Hu, X.
    Odom, D.
    Sherrill, B.
    Glueck, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials
    Blum, Joanne L.
    Kohles, Joseph
    McKenna, Edward
    Scotto, Nana
    Hu, Sylvia
    Odom, Dawn
    Kaye, James A.
    Glueck, Stefan
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (02) : 431 - 439
  • [7] Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials
    Joanne L. Blum
    Joseph Kohles
    Edward McKenna
    Nana Scotto
    Sylvia Hu
    Dawn Odom
    James A. Kaye
    Stefan Glück
    [J]. Breast Cancer Research and Treatment, 2011, 125 : 431 - 439
  • [8] Impact of eribulin on overall survival in patients with metastatic breast cancer with visceral disease.
    Vahdat, L. T.
    Cortes, J.
    Twelves, C.
    Wanders, J.
    Seegobin, S.
    Dutcus, C.
    O'Shaughnessy, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [9] Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer
    Fujii, Takaaki
    Tokuda, Shoko
    Nakazawa, Yuko
    Kurozumi, Sasagu
    Obayashi, Sayaka
    Yajima, Reina
    Shirabe, Ken
    [J]. IN VIVO, 2020, 34 (02): : 917 - 921
  • [10] Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301
    Kaufman, P. A.
    Yelle, L.
    Cortes, J.
    Perez, E. A.
    Awada, A.
    Wanders, J.
    Olivo, M. S.
    Dutcus, C. E.
    Twelves, C.
    [J]. CANCER RESEARCH, 2013, 73
12345